Vascepa Alternatives Compared
| Vascepa (icosapent) | Ozempic (semaglutide) | Repatha (evolocumab) |
|
|---|
| Vascepa (icosapent) | Ozempic (semaglutide) | Repatha (evolocumab) |
|
|||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Vascepa is a prescription, high-purity eicosapentaenoic acid (EPA - a type of omega-3 fatty acid), that may be used to lower the risk of cardiovascular disease in people with high triglyceride levels... View more |
Prescription only
Ozempic lowers blood sugar levels by mimicking the effects of GLP-1, a naturally occurring hormone that stimulates insulin secretion and lowers glucagon secretion from the liver. It is... View more |
Prescription only
Repatha is a PCSK9 inhibitor that may be used to reduce LDL-C levels in people with primary hyperlipidemia and HoFH, and also to reduce the risk of cardiovascular events in adults with established... View more |
Related suggestions Cardiovascular Risk Reduction
Popular comparisons
|
|||||||||||||||||||||||
| More about Vascepa (icosapent) | More about Ozempic (semaglutide) | More about Repatha (evolocumab) | ||||||||||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||||||||||
|
Vascepa has an average rating of 5.7 out of 10 from a total of 119 ratings on Drugs.com. 45% of reviewers reported a positive effect, while 40% reported a negative effect. |
Ozempic has an average rating of 6.6 out of 10 from a total of 1507 ratings on Drugs.com. 52% of reviewers reported a positive effect, while 23% reported a negative effect. |
Repatha has an average rating of 5.3 out of 10 from a total of 687 ratings on Drugs.com. 39% of reviewers reported a positive effect, while 46% reported a negative effect. |
||||||||||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||||||||||||||||||
View all Vascepa side effects |
View all Ozempic side effects |
View all Repatha side effects |
||||||||||||||||||||||||
| Drug Class | ||||||||||||||||||||||||||
| Generic Availability | ||||||||||||||||||||||||||
|
N/A |
||||||||||||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all Vascepa prices |
View all Ozempic prices |
View all Repatha prices |
||||||||||||||||||||||||
| Dosage Forms | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
| Brand Names | ||||||||||||||||||||||||||
|
N/A |
Other semaglutide brands include: Rybelsus, Wegovy |
N/A |
||||||||||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||||||||||||||||||
|
89 hours |
168 hours |
408 hours |
||||||||||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | ||||||||||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
| Pregnancy Category | ||||||||||||||||||||||||||
|
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||||||||||||||||||
| Drug Interactions | ||||||||||||||||||||||||||
|
A total of 76 drugs are known to interact with Vascepa:
|
A total of 273 drugs are known to interact with Ozempic:
|
A total of 2 drugs are known to interact with Repatha:
|
||||||||||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
|||||||||||||||||||||||||
| Disease Interactions | ||||||||||||||||||||||||||
|
No known disease interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||||||||||||
| First Approval Date | ||||||||||||||||||||||||||
|
July 26, 2012 |
N/A |
August 27, 2015 |
||||||||||||||||||||||||
| WADA Class View classifications | ||||||||||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||||||||||
| More Information | ||||||||||||||||||||||||||
| Patient Resources | ||||||||||||||||||||||||||
| Professional Resources | ||||||||||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.